Resumen de acción 0QOK Roche Holding AG opera en el sector farmacéutico y de diagnóstico en Europa, Norteamérica, Latinoamérica, Asia, África, Australia y Oceanía. Saber más
Recompensas Análisis de riesgos Ver todos los controles de riesgos Captura tus ideas, enlaces y narrativas de la empresa
Competidores de Roche Holding AG Historial de precios y rendimiento
Resumen de las cotizaciones máximas, mínimas y variaciones del Roche Holding Precios históricos de las acciones Precio actual de la acción CHF 269.45 Máximo en las últimas 52 semanas CHF 288.00 Mínimo de 52 semanas CHF 212.30 Beta 0.14 Cambio en 1 mes 5.82% Variación en 3 meses 0.44% Cambio de 1 año 6.76% Variación en 3 años -26.18% Variación en 5 años -17.84% Variación desde la OPV 36.02%
Noticias y actualizaciones recientes
Roche Receives FDA Clearance For VENTANA DP 600 Slide Scanner In Digital Pathology Jan 09
Roche Holding AG to Report Fiscal Year 2024 Results on Jan 30, 2025 Jan 02
Roche's Vabysmo® Prefilled Syringe Approved by European Medicines Agency for Treating Retinal Conditions Dec 13
New and Updated Data for Columvi and Lunsumio At Ash 2024 Reinforce Their Potential to Improve Outcomes for People with Lymphoma Dec 10
Five-Year Results Confirm Roche’s Polivy Combination Therapy as New Standard of Care for Previously Untreated Aggressive Lymphoma Dec 09
U.S. Food and Drug Administration Accepts Supplemental Biologics License Application for Roche’s Columvi Combination for People with Relapsed or Refractory Diffuse Large B-Cell Lymphoma Dec 05 Ver más actualizaciones
Roche Receives FDA Clearance For VENTANA DP 600 Slide Scanner In Digital Pathology Jan 09
Roche Holding AG to Report Fiscal Year 2024 Results on Jan 30, 2025 Jan 02
Roche's Vabysmo® Prefilled Syringe Approved by European Medicines Agency for Treating Retinal Conditions Dec 13
New and Updated Data for Columvi and Lunsumio At Ash 2024 Reinforce Their Potential to Improve Outcomes for People with Lymphoma Dec 10
Five-Year Results Confirm Roche’s Polivy Combination Therapy as New Standard of Care for Previously Untreated Aggressive Lymphoma Dec 09
U.S. Food and Drug Administration Accepts Supplemental Biologics License Application for Roche’s Columvi Combination for People with Relapsed or Refractory Diffuse Large B-Cell Lymphoma Dec 05
Roche Receives FDA Approval for First Companion Diagnostic to Identify Patients with Biliary Tract Cancer Eligible for Her2-Targeted Treatment with ZIIHERA Nov 25
Roche to Present New and Encouraging Long-Term Follow-Up Data Across Broad Haematology Portfolio At ASH 2024 Nov 05
Roche Presents New Data At CTAD, Demonstrating Its Growing Momentum in Diagnostics for Alzheimer’s Disease Nov 02 Roche Announces Positive Topline One-Year Results from the Open-Label, Single-Arm Phase IV ELEVATUM Study Evaluating Vabysmo® (Faricimab) for the Treatment of Diabetic Macular Edema (DME) in People from Racial and Ethnic Groups That Are Often Underrepresented in Clinical Trials
Roche Presents Positive Two-Year Data from the Ongoing Rainbowfish Study Oct 14
FDA Approves Roche’s Itovebi, A Targeted Treatment for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer with A PIK3CA Mutation Oct 11 Lonza Group AG (SWX:LONN) completed the acquisition of Genentech Manufacturing Facility in Vacaville, California from Roche Holding AG (SWX:ROG). Oct 02
Halozyme Therapeutics, Inc. Announces FDA Approval of Roche's Subcutaneous OCREVUS ZUNOVO with ENHANZE for People with Relapsing and Primary Progressive Multiple Sclerosis Sep 14
FDA Approves Roche’s Tecentriq Hybreza, the First and Only Subcutaneous Anti-PD-(L)1 Cancer Immunotherapy Sep 13 Roche's Fenebrutinib Demonstrates Near- Complete Suppression of Disease Activity and Disability Progression for Up to 48 Weeks in Patients with Relapsing Multiple Sclerosis Sep 04
Roche’s PiaSky Approves in the Eu as the First Monthly Subcutaneous Treatment for People with PNH Aug 27
New minor risk - Earnings quality Aug 01
European Commission Approves Roche’s Vabysmo for Treatment of Retinal Vein Occlusion (RVO) Jul 30
First half 2024 earnings released: EPS: CHF7.85 (vs CHF8.93 in 1H 2023) Jul 28
Roche Holding AG Raises Earnings Guidance for the Year 2024 Jul 25
BioPharma Credit PLC Notes the Update on the UK CMA (Competition and Markets Authority) Regarding the CMA's Clearance of the Proposed Acquisition of LumiraDx by Roche Jul 23 New Data for Roche’s Susvimo Demonstrates Sustained Efficacy in Two Serious Diabetic Eye Conditions Health Canada Authorizes Alecensaro (Alectinib) as the First and Only Adjuvant Treatment for People with Alk-Positive Early-Stage Lung Cancer Roche to Reintroduce Susvimo in the US for People with Neovascular Age-Related Macular Degeneration (nAMD) Jul 09
Roche Provides Update on Phase II/III SKYSCRAPER-06 Study in Metastatic Non-Small Cell Lung Cancer Jul 04
Roche Holding AG to Report Q2, 2024 Results on Jul 25, 2024 Jun 26
Roche Announces the European Commission Grants Marketing Authorisation for OCREVUS (Ocrelizumab) Subcutaneous for the Treatment of Relapsing Multiple Sclerosis and Primary Progressive Multiple Sclerosis Jun 25
Roche Launches New Highly-Sensitive Test to More Easily Diagnostic Patients Who May Have B-Cell Lymphoma Jun 20 Roche’s Phase III STARGLO study demonstrates Columvi significantly extends survival in people with relapsed or refractory diffuse large B-cell lymphoma Jun 17
Roche Holding AG Announces U.S. Food and Drug Administration Accepted the New Drug Application and Granted Priority Review to Inavolisib, an Investigational, Oral Therapy, in Combination with Palbociclib (Ibrance®) and Fulvestrant May 31
Roche Announces Management and Board Committee Changes May 28
Roche Receives FDA Device Designation for Blood Test Measuring Lp(a) May 25
Roche Reports Positive Phase I Results for Its Dual GLP-1/GIP Receptor Agonist CT-388 in People with Obesity May 18
Roche Announces FDA Approval of One of the First HPV Self- Collection Solutions in the U.S., Expanding Access and Screening Options to Help Eliminate Cervical Cancer May 16
Roche Holding AG Provides Earnings Guidance for the Year 2024 Apr 24 FDA Approves Roche’s Alecensa as the First Adjuvant Treatment for People with ALK-Positive Early-Stage Lung Cancer Apr 20
Roche Holding AG Announces Data from the Phase III OCARINA II Study (S31.006) of OCREVUS®? (ocrelizumab) Apr 17
Roche Receives FDA Breakthrough Device Designation for Blood Test to Support Early Alzheimer's Disease Diagnosis Apr 12
Roche Receives FDA Approval for the First Molecular Test to Screen for Malaria in Blood Donors Mar 27 Roche Holding AG, Annual General Meeting, Mar 12, 2024 Mar 13
Upcoming dividend of CHF9.60 per share Mar 07
Roche and Alnylam Report Positive Topline Results from the Phase II KARDIA-2 Study in People with Hypertension Mar 05
Roche Announces FDA Approves Xolair as First and Only Medicine for Children and Adults with One or More Food Allergies Feb 17
Roche Launches Three New Factor Xa Inhibitor Coagulation Tests to Meet Growing Patient Need Feb 12
Full year 2023 earnings released: EPS: CHF14.39 (vs CHF15.53 in FY 2022) Feb 07
Dividend increased to CHF9.60 Feb 04 Roche Announces New 72-Week Data from Two Global Phase III Studies, BALATON and COMINO, Evaluating Vabysmo® (Faricimab) in Macular Edema Due to Branch and Central Retinal Vein Occlusion (BRVO and CRVO) Feb 02
Roche Holding AG Proposes Dividend
Roche Holding AG (SWX:ROG) completed the acquisition of Carmot Therapeutics Inc. from a group of shareholders. Jan 30
Roche Holding AG (SWX:ROG) completed the acquisition of Carmot Therapeutics Inc. from a group of shareholders. Jan 29
European Commission Approves Roche's Tecentriq SC, the EU's First PD-(L)1 Cancer Immunotherapy Subcutaneous Injection for Multiple Cancer Types Jan 16
Roche Holding AG to Report Fiscal Year 2023 Results on Feb 01, 2024 Dec 20
Roche Announces New Data from Its CD20xCD3 T-Cell Engaging Bispecific Antibody Programme Were Presented At the 65Th American Society of Hematology Annual Meeting & Exposition Dec 12
Roche Announces New Data Reinforce the Benefit of Early Preventative Treatment with Hemlibra for Babies with Severe Haemophilia A Dec 11 Roche Presents Positive Results from the Phase III INAVO120 Study Evaluating Inavolisib in Combination with Palbociclib and Fulvestrant as a First-Line Treatment for People with PIK3CA-Mutation Roche Holding AG (SWX:ROG) entered into a definitive merger agreement to acquire Carmot Therapeutics Inc. from a group of shareholders for approximately $2.7 billion. Dec 04
Roche Expands Hepatitis Diagnostics Portfolio to Help Clinicians Diagnose and Monitor Patients with Acute or Chronic Hepatitis B Infection Nov 29
Roche Expands Hepatitis Diagnostics Portfolio to Help Clinicians Diagnose and Monitor Patients with Acute or Chronic Hepatitis B Infection Nov 28
Roche Launches Automated Serology Hepatitis E Virus Tests, Including A Test to Detect Acute Hev Infections, Recommended in the New Who 2023 Essential Diagnostics List Nov 18 Roche's Subcutaneous Injection of Tecentriq Recommends by the EU's CHMP for Multiple Cancer Types Nov 17
Roche Announces its Elecsys NfL Test Receives FDA Breakthrough Device Designation from the U.S. Food and Drug Administration Nov 09 Roche Announces EMBARK Trial in Duchenne Muscular Dystrophy Nov 01
United States Food and Drug Administration Approves Roche's Vabysmo for the Treatment of Retinal Veinocclusion (RVO) Oct 29
Roche Holding AG Confirms Outlook for 2023 Oct 19 Rentabilidad de los accionistas 0QOK GB Pharmaceuticals Mercado GB 7D 4.7% 2.9% -0.3% 1Y 6.8% -2.9% 4.9%
Ver rendimientos de los accionistas
Rentabilidad vs. Industria: 0QOK superó a la industria UK Pharmaceuticals, que obtuvo un rendimiento del -2.9% el año pasado.
Rentabilidad vs. Mercado: 0QOK superó al mercado UK, que obtuvo un rendimiento del 4.9% el año pasado.
Volatilidad de los precios Is 0QOK's price volatile compared to industry and market? 0QOK volatility 0QOK Average Weekly Movement 2.5% Pharmaceuticals Industry Average Movement 7.1% Market Average Movement 4.8% 10% most volatile stocks in GB Market 10.8% 10% least volatile stocks in GB Market 2.6%
Precio estable de las acciones: 0QOK no ha tenido una volatilidad de precios significativa en los últimos 3 meses en comparación con el mercado UK.
Volatilidad a lo largo del tiempo: La volatilidad semanal de 0QOK (2%) se ha mantenido estable durante el año pasado.
Acerca de la empresa Fundada Empleados CEO Página web 1896 103,605 Thomas Schinecker www.roche.com
Roche Holding AG opera en el sector farmacéutico y de diagnóstico en Europa, Norteamérica, Latinoamérica, Asia, África, Australia y Oceanía. La empresa ofrece productos farmacéuticos en las áreas terapéuticas de anemia, tumores sanguíneos y sólidos, dermatología, hemofilia, enfermedades inflamatorias y autoinmunes, trastornos neurológicos, oftalmología, trastornos respiratorios y trasplantes. También está desarrollando productos para diversas áreas terapéuticas.
Mostrar más Resumen de fundamentos de Roche Holding AG ¿Cómo se comparan los beneficios e ingresos de Roche Holding con su capitalización de mercado? Estadísticas fundamentales de 0QOK Capitalización bursátil CHF 215.01b Beneficios(TTM ) CHF 10.62b Ingresos (TTM ) CHF 60.58b
20.0x Ratio precio-beneficio (PE)
3.5x Ratio precio-ventas (PS) Beneficios e Ingresos Estadísticas clave de rentabilidad del último informe de resultados (TTM) Cuenta de resultados (TTM ) de 0QOK Ingresos CHF 60.58b Coste de los ingresos CHF 15.43b Beneficio bruto CHF 45.16b Otros gastos CHF 34.54b Beneficios CHF 10.62b
Últimos beneficios comunicados
Jun 30, 2024
Próxima fecha de beneficios
Jan 30, 2025
Beneficios por acción (BPA) 13.33 Margen bruto 74.54% Margen de beneficio neto 17.53% Ratio deuda/patrimonio 104.8%
¿Cómo se ha desempeñado 0QOK a largo plazo?
Ver rendimiento histórico y comparativa Dividendos
3.6% Rentabilidad actual por dividendo
Análisis de la empresa y estado de los datos financieros Datos Última actualización (huso horario UTC) Análisis de la empresa 2025/01/11 10:11 Precio de las acciones al final del día 2025/01/10 00:00 Beneficios 2024/06/30 Ingresos anuales 2023/12/31
Fuentes de datos Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC . Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
Paquete Datos Marco temporal Ejemplo Fuente EE.UU. * Finanzas de la empresa 10 años Cuenta de resultados Estado de tesorería Balance Estimaciones del consenso de analistas +3 años Previsiones financieras Objetivos de precios de los analistas Precios de mercado 30 años Precios de las acciones Dividendos, escisiones y acciones Propiedad 10 años Accionistas principales Información privilegiada Gestión 10 años Equipo directivo Consejo de Administración Principales avances 10 años
* ejemplo para los valores estadounidenses, para los no estadounidenses se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Obtenga más información aquí .
Modelo de análisis y copo de nieve Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github , también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube .
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en .
Fuentes analistas Roche Holding AG está cubierta por 58 analistas. 16 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
Analista Institución Kamla Singh AlphaValue John Staszak Argus Research Company Gerhard Schwarz Baader Helvea Equity Research
Mostrar 55 más analistas 
